Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Glatting

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2007
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLTAndreas K Buck, Clemens Kratochwil, Gerhard Glatting, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 26, 2020
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST PatientsLeonhard Gruber, Luis David Jiménez-Franco, Clemens Decristoforo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2007
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanomaFelix M Mottaghy, Cord Sunderkötter, Roland Schubert, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 4, 2011
New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitorsAgnieszka Morgenroth, Elizaveta A Urusova, Cornelia Dinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 16, 2004
Clinical relevance of imaging proliferative activity in lung nodulesAndreas K Buck, Martin Hetzel, Holger Schirrmeister, et al.
Journal of Neuro-Oncology|January 22, 2015
In vivo micro-CT imaging of untreated and irradiated orthotopic glioblastoma xenografts in mice: capabilities, limitations and a comparison with bioluminescence imagingStefanie Kirschner, Manuela C Felix, Linda Hartmann, et al.
Thyroid : Official Journal of the American Thyroid Association|May 11, 2010
Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinomaMarkus Luster, Wolfram Karges, Katrin Zeich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 3, 2006
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemiaGerhard Glatting, Marguerite Müller, Bernd Koop, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 29, 2009
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytomaMarkus Luster, Wolfram Karges, Katrin Zeich, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 22, 2014
Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancerYasser Abo-Madyan, Muhammad Hammad Aziz, Moamen M O M Aly, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2007
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLTAndreas K Buck, Clemens Kratochwil, Gerhard Glatting, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 26, 2020
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST PatientsLeonhard Gruber, Luis David Jiménez-Franco, Clemens Decristoforo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2007
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanomaFelix M Mottaghy, Cord Sunderkötter, Roland Schubert, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 4, 2011
New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitorsAgnieszka Morgenroth, Elizaveta A Urusova, Cornelia Dinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 16, 2004
Clinical relevance of imaging proliferative activity in lung nodulesAndreas K Buck, Martin Hetzel, Holger Schirrmeister, et al.
Journal of Neuro-Oncology|January 22, 2015
In vivo micro-CT imaging of untreated and irradiated orthotopic glioblastoma xenografts in mice: capabilities, limitations and a comparison with bioluminescence imagingStefanie Kirschner, Manuela C Felix, Linda Hartmann, et al.
Thyroid : Official Journal of the American Thyroid Association|May 11, 2010
Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinomaMarkus Luster, Wolfram Karges, Katrin Zeich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 3, 2006
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemiaGerhard Glatting, Marguerite Müller, Bernd Koop, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 29, 2009
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytomaMarkus Luster, Wolfram Karges, Katrin Zeich, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 22, 2014
Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancerYasser Abo-Madyan, Muhammad Hammad Aziz, Moamen M O M Aly, et al.
Pageof 15